News | May 28, 2025
Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Subscribe To Our Newsletter & Stay Updated
